Business
Alzheimer’s drug aducanumab faces major setback as US authorities consider whether to approve it – ABC News
A drug company is seeking to get an experimental Alzheimer’s drug approved by the FDA. If they succeed it would be a major breakthrough. But just how convincing…
For almost two decades, the field of Alzheimer’s research has been dogged by treatment failures, leaving patients and their families desperate for hope.
But the makers of a new experimental drug, currently under consideration for regulatory approval by the US Food and Drug Administration (FDA), want to change that.
If Aducanumab, developed by pharmaceutical company Biogen, is approved by the FDA, it would be the first Alzheimer’s drug to be greenlit in 20 years.
Last week, Biogen’s stock price soared…
-
Noosa News23 hours agoBrisbane’s covert cameras catching more than just litterbugs
-
Business9 hours ago1 ASX dividend stock down 43% I’d buy right now
-
Noosa News9 hours agoMeasles alert: Australia Zoo, Hospital ED, Sushi Hub, Holey Moley Mini Golf and train stations among QLD infection sites
-
Business13 hours agoBattle of the ASX ETFs: Why has VGS outperformed VTS this year?